Henrik Depenbrock Selected Research

necitumumab

1/2018	Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
10/2017	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
1/2017	An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
1/2016	Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
7/2015	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
3/2015	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Henrik Depenbrock Research Topics

Disease

6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 03/2015
5	Disease Progression 10/2017 - 03/2015
3	Exanthema (Rash) 01/2017 - 03/2015
2	Neoplasms (Cancer) 01/2018 - 01/2016
1	Acne Vulgaris 07/2015

Drug/Important Bio-Agent (IBA)

6	necitumumabIBA 01/2018 - 03/2015
5	Cisplatin (Platino)FDA LinkGeneric 10/2017 - 03/2015
4	Gemcitabine FDA Link 10/2017 - 07/2015
3	ErbB Receptors (EGF Receptor)IBA 01/2018 - 01/2016
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2016
1	AntibodiesIBA 07/2015
1	Pemetrexed (MTA)FDA Link 03/2015

Therapy/Procedure

4	Therapeutics 01/2018 - 03/2015
3	Drug Therapy (Chemotherapy) 01/2017 - 03/2015